Clinical Trials · NCT00349557
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Benaroya Research Institute
- Enrollment
- 18
- Start date
- Apr 2006
- Locations
- 1 site, United States
- Primary endpoint
- To determine the acute (within 90 days from 1st day of radiation therapy) toxicities from intensity modulated radiation therapy (IMRT) in conjunction with bevacizumab, bicalutamide, and goserelin.